Topcon Healthcare announced a strategic investment in Senseye, Inc, a company developing an ocular biomarker–based diagnostic platform for mental health disorders.

Senseye’s technology uses AI and computer vision to analyze pupil dynamics and eye movements captured via smartphone camera, translating the data into validated digital biomarkers to support diagnosis and monitoring of posttraumatic stress disorder (PTSD), major depressive disorder (MDD), and generalized anxiety disorder (GAD).

This marks Topcon’s first investment in neuropsychiatry-related technology and aligns with its “Healthcare from the Eye” initiative, which seeks to leverage ocular imaging as a window into systemic disease. According to the company, the technology is intended to extend objective mental health screening into primary care settings, including underserved areas with limited behavioral health resources. Eyecare providers may also use the platform to flag potential neuropsychiatric concerns during routine eye exams and refer patients for further evaluation.

Topcon said the collaboration lays the groundwork for integrating Senseye’s technology into Harmony, its connected care platform. Embedding the solution into Harmony would expand its diagnostic modules—currently focused on imaging, AI analytics, and data sharing—to encompass mental health, providing a more comprehensive view of patient well-being through the eye. RP